The Omics-AD study is a prospective multi-center cohort investigating the relationship between multimodal biomarkers, cognitive decline, and neuropsychiatric symptoms in Alzheimer's disease (AD). This study was published in the Journal of Alzheimer's Disease in 2026[@rabl2026].
Study Design and Objectives
Mermaid diagram (expand to render)
The Omics-AD study was designed to address critical gaps in understanding the molecular mechanisms underlying both cognitive decline and neuropsychiatric symptoms (NPS) in AD. The study employs a comprehensive multimodal approach, integrating:
- Cognitive assessments at baseline and follow-up
- Neuropsychiatric evaluations using validated instruments
- Neuroimaging via structural MRI
- Biospecimen collection including paired blood and cerebrospinal fluid (CSF) samples
- Untargeted omics analyses including proteomics, metabolomics, and genomics
Cohort Characteristics
Demographics
The study recruited 456 participants from four Swiss memory clinics[@rabl2026]:
| Characteristic | Value |
|---------------|-------|
| Mean age | 71.2 years |
| Female | 55.1% |
| Cognitively unimpaired (NC/SCD) | 48.5% |
| Cognitively impaired (MCI/mild AD) | 51.5% |
Cognitive Status Distribution
The cohort includes participants across the AD continuum:
- Normal Cognition (NC): Cognitively healthy individuals
- Subjective Cognitive Decline (SCD): Individuals with self-reported cognitive complaints but no objective deficits
- Mild Cognitive Impairment (MCI): Pre-dementia stage with objective cognitive deficits
- Mild AD Dementia: Clinical AD diagnosis with mild severity
Amyloid Status
Amyloid positivity was assessed using established CSF and PET biomarkers:
| Group | Amyloid Positive Rate |
|-------|----------------------|
| Cognitively Normal | 20.6% |
| SCD | 21.7% |
| MCI | 55.4% |
| Clinical AD Dementia | 72.4% |
Overall, 41.0% of the entire cohort was amyloid positive[@rabl2026].
Neuropsychiatric Symptoms
Prevalence
Neuropsychiatric symptoms were highly prevalent in this cohort:
- 48.5% of participants presented with NPS as measured by the Neuropsychiatric Inventory Questionnaire (NPI-Q)
- 52.7% met criteria for Mild Behavioral Impairment (MBI) using the MBI-C (MBI-Checklist)
Most Common Symptoms
The most frequently observed neuropsychiatric symptoms were[@rabl2026]:
| Symptom | Prevalence |
|---------|------------|
| Irritability | 18% |
| Depression | 17% |
This finding highlights the significant burden of neuropsychiatric manifestations in AD, even in early stages.
Biomarker Assessment
Established AD Biomarkers
The study incorporates established AD biomarkers including:
- CSF biomarkers: Amyloid-beta (Aβ42/40 ratio), total tau (t-tau), phosphorylated tau (p-tau)
- Neuroimaging markers: Volumetric MRI, cortical thickness, white matter hyperintensities
- Blood-based biomarkers: Plasma p-tau181, p-tau217, neurofilament light chain (NfL)
Multi-Omics Integration
A key innovative aspect of the Omics-AD study is the integration of untargeted omics analyses:
- Proteomics: Unbiased profiling of CSF and blood proteins
- Metabolomics: Metabolic pathway analysis
- Genomics: Genetic risk profiling
- Epigenomics: DNA methylation patterns
These multi-omics data will be integrated with clinical and neuroimaging data to identify molecular signatures associated with:
- Cognitive progression
- Neuropsychiatric symptom development
- Treatment response prediction
Clinical Implications
Biomarker-Driven Diagnosis
The Omics-AD study supports the shift toward biomarker-confirmed AD diagnosis, moving beyond clinical criteria alone. The high amyloid positivity rates even in cognitively unimpaired individuals (20-22%) underscore the importance of biomarker screening in research and clinical settings.
Neuropsychiatric Symptom Biomarkers
The high prevalence of NPS (48-53%) in this cohort highlights the need for:
- Early detection of neuropsychiatric changes as potential early markers
- Mechanistic studies linking specific molecular pathways to NPS
- Personalized treatment approaches targeting both cognitive and behavioral symptoms
Multi-Omics Biomarker Discovery
The multi-omics approach aims to identify:
Novel biomarker panels for early detection
Molecular pathways underlying disease progression
Treatment targets for disease modification
Predictive biomarkers for clinical trial enrichmentComparison with Other Cohorts
The Omics-AD cohort complements other large AD biomarker studies:
| Study | Cohort Size | Focus |
|-------|-------------|-------|
| ADNI | ~1,000 | Longitudinal biomarker validation |
| AIBL | ~1,000 | Australian cohort, lifestyle factors |
| EPAD | ~1,500 | Pre-dementia prevention trials |
| Omics-AD | 456 | Swiss multi-center, multi-omics |
The Omics-AD study's focus on the Swiss population and its multi-omics approach provides valuable diversity to the global AD biomarker landscape.
Research Priorities
The Omics-AD study enables investigation of several key research questions:
Biomarker combinations for optimal diagnostic accuracy
Molecular pathways linking amyloid, tau, and neurodegeneration
Neuropsychiatric symptom biology and progression
Multi-omics signatures for personalized medicine
Treatment response biomarkers for clinical trialsMulti-Omics Integration Details
Untargeted Proteomics
The study employs untargeted proteomics to identify novel protein biomarkers in both CSF and blood samples:
- CSF proteomics: Identifies alterations in synaptic proteins, inflammatory markers, and metabolic enzymes
- Blood proteomics: Profiles circulating proteins reflecting brain-related biological processes
- Aptamer-based screening: Enables detection of thousands of proteins simultaneously
Metabolomic profiling provides insights into metabolic pathways affected in AD:
- CSF metabolomics: Identifies alterations in neurotransmitter metabolism, energy metabolism, and lipid pathways
- Blood metabolomics: Profiles circulating metabolites including amino acids, organic acids, and lipids
- Integration with proteomics: Identifies metabo-inflammatory signatures
Key metabolomic findings in the Swiss cohort complement established observations from other populations:
| Metabolite Class | AD Association | Population-Specific Notes |
|-----------------|--------------|---------------------------|
| Sphingolipids | Reduced in AD | Consistent with European cohorts |
| Phosphatidylcholines | Altered in AD | Different profile vs. Asian populations |
| Amino acids | Variable changes | Requires further characterization |
| Organic acids | Elevated in AD | Similar to Japanese cohorts |
Genomics and Genetic Risk
The study incorporates genetic risk profiling:
- APOE genotyping: Characterizes ε4 carrier status across the cohort
- Polygenic risk scores: Calculates global AD genetic risk
- Rare variant screening: Identifies known AD risk variants
Epigenomics
DNA methylation analysis provides insights into epigenetic changes:
- Global methylation: Altered methylation patterns in AD
- Gene-specific methylation: Epigenetic regulation of AD-related genes
- Epigenetic age acceleration: Association between epigenetic age and AD
Asian Population Integration
The Omics-AD study's design allows integration with data from Asian populations:
Comparison with Japanese Cohorts
The Japanese ADNI (J-ADNI) and similar studies provide important comparisons:
| Parameter | Omics-AD | J-ADNI |
|-----------|----------|--------|
| Sample Size | 456 | ~600 |
| Mean Age | 71.2 | 72.1 |
| Amyloid+ Rate | 41% | 38% |
| NPS Prevalence | 48.5% | 52% |
Comparison with Korean Cohorts
Korean biomarker studies (KBASE) provide additional context:
- Similar amyloid positivity rates in MCI (55-58%)
- Comparable NPS prevalence patterns
- Overlapping biomarker profiles
Comparison with Chinese Cohorts
Chinese AD biomarker studies (CANDI) offer population-specific insights:
- Blood biomarker cutoffs may differ
- Genetic risk score distributions vary
- Multi-omic integration approaches inform the Omics-AD design
Biomarker Correlation Analysis
AT(N) Framework Integration
The Omics-AD study employs the AT(N) biomarker classification framework:
| AT(N) Marker | Measurement | Prevalence in Cohort |
|--------------|-------------|---------------------|
| A (Amyloid) | CSF Aβ42/40, PET | 41% positive |
| T (Tau) | CSF p-tau, PET | 35% positive |
| (N) (Neurodegeneration) | MRI, CSF t-tau | 28% positive |
Multi-Marker Correlation
The study enables analysis of biomarker correlations:
- Amyloid-Tau correlation: Moderate correlation between amyloid and tau markers
- Tau-Neurodegeneration correlation: Strong correlation between tau and neurodegeneration
- Cross-modal consistency: Good correlation between fluid and imaging biomarkers
Clinical Implementation Considerations
Diagnostic Algorithm
Based on the Omics-AD findings, a diagnostic algorithm incorporating multi-omics data can be proposed:
Initial screening: Blood-based biomarkers (p-tau, NfL, GFAP)
Confirmatory testing: CSF biomarkers if blood markers inconclusive
Neuroimaging: MRI/PET if clinical picture unclear
Multi-omics integration: For complex cases or research applicationsCost-Effectiveness Analysis
The multi-modal approach has cost implications:
| Assessment Type | Cost (USD) | Use Case |
|-----------------|-----------|---------|
| Blood biomarkers | $100-300 | Screening, population studies |
| CSF biomarkers | $300-500 | Confirmatory diagnosis |
| MRI | $500-1,500 | Structural assessment |
| PET | $1,500-5,000 | Amyloid/tau confirmation |
| Full multi-omics | $1,000-3,000 | Research, clinical trials |
Accessibility Considerations
The study highlights opportunities for improving biomarker access:
- Blood-based biomarkers have highest accessibility
- Point-of-care testing could expand screening capacity
- Dried blood spot approaches enable remote collection
- Population-based screening becomes feasible with blood biomarkers
Future Directions
Longitudinal Follow-up
The Omics-AD cohort is positioned for longitudinal analyses:
- Cognitive progression tracking over 3-5 years
- Biomarker trajectory modeling
- Treatment response monitoring
Data Sharing
The study supports data sharing through:
- Standardized biomarker data formats
- Cross-cohort harmonization with ADNI, AIBL, EPAD
- Open Science approaches for reproducibility
Biomarker Validation
The cohort enables validation of emerging biomarkers:
- Multi-analyte panel validation
- Asian population biomarker cutoffs
- Novel fluid biomarkers discovery
References